CGEM: Cullinan Oncology Price-to-Revenue Multiple

Symbol and logo of brand Cullinan Oncology (CGEM)

A steady influx of funds from a partnership with a pharma behemoth makes Cullinan Therapeutics (CGEM) independent of market cycles. On GURU.Markets, the price-to-sales ratio demonstrates the dynamics of capitalization relative to sales, where the value of 34.60 expresses the metric level. The company's growth relies on multimodal tumor therapy, with the promising drug CLN-978 and a significant liquidity reserve serving as key drivers.

CGEM Cullinan Corp Market Cap to Revenue (07/04/2022 - 08/07/2022)

Analytical breakdowns for Cullinan Therapeutics, Inc. (CGEM)

- share price and consensus valuation forecast:
Price Performance Chart Cullinan Therapeutics, Inc.|CGEM - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Cullinan Corp|CGEM - Enterprise Value
- book capitalization data:
Net Asset Value per Share Cullinan Therapeutics|CGEM - Company Net Assets|Market Cap to Book Value Multiple cullinanoncology.com|CGEM - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Cullinan Therapeutics|CGEM - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Cullinan Therapeutics, Inc.|CGEM - Company Total Debt|Debt to Net Assets Ratio Cullinan Therapeutics, Inc.|CGEM - Company Long-Term Liabilities|Amount of Current Liabilities Cullinan Therapeutics|Intermediate Coverage Ratio cullinanoncology.com
- earnings and multiples data:
CGEM - Net Profit|Expected Net Profit Cullinan Therapeutics|CGEM - Price to Earnings Ratio|Future Price to Earnings Multiple Cullinan Therapeutics Inc|CGEM - PEG Multiple|EV/EBITDA Multiple Cullinan Therapeutics|CGEM - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Cullinan Therapeutics|CGEM - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months cullinanoncology.com|CGEM - Earnings growth in current year|Expected earnings per share growth for next year Cullinan Therapeutics
- sales revenue and business income indicators:
CGEM - Company Sales|Projected Sales Volume Cullinan Oncology|CGEM - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Cullinan Therapeutics|CGEM - Sales Growth YoY (Last Twelve Months)
Summary company analytics:Cullinan Therapeutics Inc, CGEM
Mass-produced product of cullinanoncology.com

Investors use this indicator to determine the degree of overpayment per unit of income, assessing market expectations regarding the issuer's future success. The ratio of market capitalization to annual revenue, reflected in the price-to-sales ratio, allows for a comparison of Cullinan Therapeutics (CGEM) valuation against the efficiency of oncology drug development on contract capacities, filtering out short-term market noise from the fundamental analysis.

Who Cullinan Therapeutics competes with

GMAB (Genmab) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis Inc)|Price-to-Revenue Multiple Nuvalent Corp|Kymera Therapeutics, Inc. - P/S Multiple|Price to Sales IDEAYA Biosciences, Inc.|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|RLAY (relaytx.com) - P/S Multiple|Price to Sales Nurix Pharma NRIX|P/S Multiple TYRA|Verastem - Market Cap to Revenue Ratio|Monte Rosa Therapeutics, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales propanc.com PPCB|Price-to-Revenue Ratio Cyclacel Pharmaceuticals (BGMS)|AADI (Aadi Bioscience, Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics Inc)|P/S Multiple Blueprint Medicines BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX